<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55514">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02135432</url>
  </required_header>
  <id_info>
    <org_study_id>F140319002</org_study_id>
    <secondary_id>TOPIC Trial</secondary_id>
    <nct_id>NCT02135432</nct_id>
  </id_info>
  <brief_title>TOPIC Trial for COPD</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Pilot Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The TOPIC Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, double-blind, placebo-controlled, multiple-dose, pilot  study of
      orally-administered ivacaftor in subjects with chronic obstructive pulmonary disease.
      Subjects will be administered the study drug ivacaftor 150 mg (or placebo) twice daily
      (BID).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in COPD as measured by lung function</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the efficacy of ivacaftor treatment in patients with COPD including measures of CFTR activity and clinical outcome as measured by change in lung function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in COPD as measured bysweat analysis</measure>
    <time_frame>baseline and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the efficacy of ivacaftor treatment in patients with COPD including measures of CFTR activity and clinical outcome as measured by change sweat analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in COPD as measured by nasal potential difference measurements</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the efficacy of ivacaftor treatment in patients with COPD including measures of CFTR activity and clinical outcome as measured by change nasal potential difference measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean number of adverse events experienced by the Ivacaftor subjects and placebo subjects.</measure>
    <time_frame>baseline through 6 months (visit 5)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>mean number of adverse events per subject in each the Ivacaftor subjects and placebo subjects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetics as described by AUC12 of subjects receiving ivacaftor</measure>
    <time_frame>at 6 months post baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Ivacaftor (VX-770)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice a day administration of Ivacaftor: 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor</intervention_name>
    <arm_group_label>Ivacaftor (VX-770)</arm_group_label>
    <other_name>Kalydeco</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female age 40-65

          -  A Clinical diagnosis of COPD as defined by GOLD

          -  At Least a 10 pack year smoking history

          -  Exhibit symptoms of chronic bronchitis defined by MRC

          -  FEV1% predicted ≥ 35% and ≤70% Post Bronchodilator

          -  Clinically stable in the last 4 weeks with no evidence of COPD exacerbation

          -  Weight of 40 kg-120 kg

          -  Willingness to use at least one form of acceptable birth control including
             abstinence, condom with spermicide, or hormonal contraceptives

          -  Willing to monitor blood glucose if known history of diabetes mellitus requiring
             insulin or medical therapy

        Exclusion Criteria:

          -  Current Diagnosis of Asthma

          -  Daytime use of Oxygen Therapy

          -  Documented history of drug abuse within the last year

          -  Subjects should not have a pulmonary exacerbation or changes in therapy for pulmonary
             disease within 28 days before receiving the first dose of study drug.

          -  Cirrhosis or elevated liver transaminases &gt; 3X ULN

          -  GFR &lt; 50 estimated by Cockroft-Gault

          -  Any illness of abnormal lab finding that, in the opinion of the investigator or the
             subject's general practitioner, might confound the results of the study or pose an
             additional risk in administering study drug to the subject.

          -  Pregnant or Breastfeeding

          -  Subjects taking any inhibitors or inducers of CYP3A4, including certain herbal
             medications and grapefruit/grapefruit juice.

          -  Uncontrolled Diabetes

          -  Excluded medications and foods incude the drugs and foods provided in the appendix
             document.

          -  Clinically significant arrhythmias or conduction abnormalities that in the opinion of
             the investigator affect patient safety have been added as exclusion criteria and
             criteria for withdrawal.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Y Hathorne, MAE</last_name>
      <phone>205-638-9568</phone>
      <email>hhathorne@peds.uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ginger A Reeves, BS</last_name>
      <phone>638-5970</phone>
      <email>greeves@peds.uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven M Rowe, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Dransfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive pulmonary disease, Ivacaftor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
